Gossamer Bio (NASDAQ:GOSS) Announces Earnings Results

Gossamer Bio (NASDAQ:GOSS) released its earnings results on Tuesday. The company reported ($7.36) earnings per share for the quarter, missing the consensus estimate of ($3.79) by ($3.57), FiscalAI reports. The business had revenue of $38.43 million during the quarter, compared to the consensus estimate of $12.16 million.

Gossamer Bio Stock Up 5.9%

Shares of GOSS traded up $0.63 during midday trading on Tuesday, reaching $11.28. 99,581 shares of the stock were exchanged, compared to its average volume of 236,431. Gossamer Bio has a 12-month low of $8.29 and a 12-month high of $309.60. The firm has a 50 day simple moving average of $10.76 and a 200-day simple moving average of $37.05. The company has a market cap of $68.93 million, a price-to-earnings ratio of -0.20 and a beta of 2.28.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GOSS shares. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research report on Tuesday, July 28th. Chardan Capital reaffirmed a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. Weiss Ratings lowered shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Finally, Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Gossamer Bio presently has a consensus rating of “Hold” and an average price target of $256.00.

Gossamer Bio Company Profile

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.